Showing results (151-160 of 183) with videos related to
Sort By:
Pageof 19
Breast Cancer Research and Treatment|March 1, 2022
Definitive results of a phase III adjuvant trial comparing six cycles of FEC-100 to four cycles of AC in women with operable node-negative breast cancer: the NSABP B-36 trial (NRG Oncology)Charles E Geyer, Hanna Bandos, Priya Rastogi, et al.Breast Cancer Research and Treatment|April 23, 2019
Clinico-pathologic and mammographic characteristics of inflammatory and non-inflammatory breast cancer at six centers in North AfricaCatherine Schairer, Ahmed Hablas, Ibrahim AbdelBar Seif Eldein, et al.Frontiers in Oncology|June 12, 2023
Replication of genetic associations of chemotherapy-related cardiotoxicity in the adjuvant NSABP B-31 clinical trialPooja P Advani, Kathryn J Ruddy, Joerg Herrmann, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 11, 2019
NSABP B-47/NRG Oncology Phase III Randomized Trial Comparing Adjuvant Chemotherapy With or Without Trastuzumab in High-Risk Invasive Breast Cancer Negative for HER2 by FISH and With IHC 1+ or 2Louis Fehrenbacher, Reena S Cecchini, Charles E Geyer, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 24, 2024
Utility of the 70-Gene MammaPrint Assay for Prediction of Benefit From Extended Letrozole Therapy in the NRG Oncology/NSABP B-42 TrialPriya Rastogi, Hanna Bandos, Peter C Lucas, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 14, 2013
Definitive results of a phase III adjuvant trial comparing three chemotherapy regimens in women with operable, node-positive breast cancer: the NSABP B-38 trialSandra M Swain, Gong Tang, Charles E Geyer, et al.The Lancet. Oncology|October 8, 2013
Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trialAndré Robidoux, Gong Tang, Priya Rastogi, et al.JAMA Oncology|March 28, 2024
Tumor Intrinsic Subtypes and Gene Expression Signatures in Early-Stage ERBB2/HER2-Positive Breast Cancer: A Pooled Analysis of CALGB 40601, NeoALTTO, and NSABP B-41 TrialsAranzazu Fernandez-Martinez, Mattia Rediti, Gong Tang, et al.The Lancet. Oncology|August 15, 2015
Neoadjuvant plus adjuvant bevacizumab in early breast cancer (NSABP B-40 [NRG Oncology]): secondary outcomes of a phase 3, randomised controlled trialHarry D Bear, Gong Tang, Priya Rastogi, et al.The Lancet. Oncology|December 5, 2018
Use of letrozole after aromatase inhibitor-based therapy in postmenopausal breast cancer (NRG Oncology/NSABP B-42): a randomised, double-blind, placebo-controlled, phase 3 trialEleftherios P Mamounas, Hanna Bandos, Barry C Lembersky, et al.Pageof 19